CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies
Brief description of study
If you have been diagnosed with a B cell type cancer that has relapsed (come back) or is refractory (did not respond to previous treatment). The types of B cell cancers in this study include follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), or diffuse large B-cell lymphoma (DLBCL). The main goal of this study is to investigate the safety and effectiveness of an experimental drug called voruciclib as a potential treatment for different types of lymphoma.
Clinical Study Identifier: s18-00023
ClinicalTrials.gov Identifier: NCT03547115
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
